23 June 2022
3 February 2022
“At Theramex, we welcome any initiative or approach that gives women greater choice and access to menopause treatment. The decision to consider making local hormone treatment, vaginal oestrogen, available over the counter shows menopause is climbing the health agenda, which is positive news. However, the prioritisation of menopause has been a long time coming and access to menopause medicines is still sporadic across the UK, something we are working with the community to change,” said Rob Stewart, Theramex CEO.
“Women have individual needs when it comes to treatment, and it is important that those experiencing menopause have the necessary resources and access to medical advice to make an informed decision about their health.”
“We look forward to collaborating as part of the upcoming consultation to ensure that any new initiative reduces inequalities in access to treatment and doesn’t exacerbate existing issues. We strongly support the need for widespread education on menopause and the full range of approved medicines, for both healthcare professionals and patients, to ensure all women receive the best possible care.”
THX_GB_IWEB_006461 Date of Prep February 2022